EU approves Bayer's new long-term contraceptive: firm

German drug maker Bayer said on Wednesday that European Union authorities had given the go-ahead for a new contraceptive which can prevent pregnancies for up to three years.

Bayer said in a statement that its healthcare division "has successfully concluded the European registration procedure for its new low dose -releasing intrauterine system (IUS)."

IUS is "a long-term placed in the uterus for the prevention of pregnancy for up to three years."

First launches of the product—which will be marketed under the name "Jaydess"—are expected in the second quarter of 2013 in the EU, the statement said.

Bayer also applied for US marketing authorisation for the product in December 2011.

add to favorites email to friend print save as pdf

Related Stories

Bayer rules out increasing bid for Schiff Nutrition

Nov 20, 2012

German chemicals and pharmaceuticals giant Bayer withdrew from a battle to buy US-based Schiff Nutrition International on Tuesday, ruling out an increase to its bid against a rival counter offer.

ACOG: Intrauterine device insertion linked to weight loss

May 07, 2012

(HealthDay) -- Women who undergo postpartum or interval insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) or Copper T 380A (CU-T) intrauterine devices experience weight loss in the two years ...

Bayer unveils a faster-acting aspirin

May 29, 2011

Bayer AG is looking for a speedy remedy for stagnant aspirin sales. The company is introducing a reformulated aspirin today that works in half the time of its regular aspirin.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.